Rafferty Asset Management, LLC Cytom X Therapeutics, Inc. Transaction History

Rafferty Asset Management, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$2.67 - $4.68 $406,825 - $713,086	-152,369 Closed	0 $0
Q4 2021 Feb 10, 2022	SELL	$3.87 - $7.39 $22,956 - $43,837	-5,932 Reduced 3.75%	152,369 $660,000
Q3 2021 Nov 10, 2021	SELL	$4.32 - $6.43 $159,775 - $237,813	-36,985 Reduced 18.94%	158,301 $806,000
Q2 2021 Aug 10, 2021	BUY	$6.33 - $9.91 $206,541 - $323,353	32,629 Added 20.06%	195,286 $1.24 Million
Q1 2021 May 10, 2021	BUY	$6.6 - $9.0 $963,270 - $1.31 Million	145,950 Added 873.59%	162,657 $1.26 Million
Q4 2020 Feb 10, 2021	SELL	$6.47 - $7.9 $207,693 - $253,597	-32,101 Reduced 65.77%	16,707 $109,000
Q3 2020 Nov 13, 2020	BUY	$6.55 - $8.83 $174,478 - $235,213	26,638 Added 120.15%	48,808 $325,000
Q2 2020 Aug 07, 2020	BUY	$7.4 - $14.64 $164,058 - $324,568	22,170 New	22,170 $185,000
Q4 2019 Feb 10, 2020	SELL	$5.17 - $8.91 $338,686 - $583,694	-65,510 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$7.38 - $12.25 $52,626 - $87,354	-7,131 Reduced 9.82%	65,510 $483,000
Q2 2019 Aug 09, 2019	SELL	$9.35 - $11.41 $166,934 - $203,714	-17,854 Reduced 19.73%	72,641 $815,000
Q1 2019 May 15, 2019	BUY	$9.5 - $19.16 $859,702 - $1.73 Million	90,495 New	90,495 $973,000

50.4M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $58.7M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.